Tempest Registers 9.5M Shares for Resale from September Private Placement
TPST sits 17% above its 52-week low of $0.743 on light trading volume (0.1× avg).
Summary
Tempest Therapeutics registered 9.5M shares for resale underlying warrants from its September private placement, with potential cash proceeds of $5.22M if all warrants are exercised.
Updates
· SEC 424B3 — The 424B3 prospectus registers the same 9,534,164 warrant shares for resale, with potential gross proceeds of $5.22 million if all warrants are exercised for cash.
Key Events · Financing and Capital Events · TPST
-
9.5M Shares Registered for Resale
S-3 registers up to 9,534,164 shares underlying warrants from the September 11, 2026 private placement: 3,105,591 pre-funded warrants, 3,105,591 Series C warrants, 3,105,591 Series D warrants, and 217,391 placement agent warrants.
-
Potential $5.22M Cash Proceeds
If all warrants are exercised for cash, Tempest would receive approximately $5.22 million. Pre-funded warrants are exercisable at $0.001; common warrants at $0.805; placement agent warrants at $1.0063.
-
Stockholder Approval Required
Common warrants become exercisable only after stockholder approval, which the company must seek within 90 days of the September 11, 2026 purchase agreement.
-
Placement Agent Compensation
H.C. Wainwright received a 7.0% cash fee on gross proceeds plus placement agent warrants for 217,391 shares at $1.0063 per share.
Analysis · TPST · Life Sciences
Tempest Therapeutics filed an S-3 to register the resale of up to 9,534,164 shares underlying warrants issued in its September 11, 2026 private placement. The filing quantifies the full warrant structure: 3.1M pre-funded warrants exercisable at $0.001, 3.1M Series C warrants and 3.1M Series D warrants exercisable at $0.805, plus 217,391 placement agent warrants at $1.0063. If all warrants are exercised for cash, the company would receive approximately $5.22 million — meaningful runway for a company that reported only $0.8M in cash as of August 13, 2026. The registration also creates a potential overhang of 9.5M shares against 16.9M currently outstanding, though the company receives no proceeds from resales by selling stockholders.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.74 to $12.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.